Overview

Location [1]
5q35.2
Pathway
Receptor tyrosine kinase/growth factor signaling
Protein [2]
Fibroblast growth factor receptor 4
Synonyms [1]
TKF, JTK2, CD334

Fibroblast growth factor receptor 4 (FGFR4) is a gene that encodes a protein with a tyrosine kinase domain and three immunoglobulin-like domains. The protein functions in mitogenesis and differentiation. Missense mutations, nonsense mutations, silent mutations, and frameshift insertions and deletions are observed in cancers such as endometrial cancer, intestinal cancer, and skin cancer.

FGFR4 is altered in 1.82% of all cancers with non-small cell lung carcinoma, breast carcinoma, colorectal adenocarcinoma, melanoma, and malignant glioma having the greatest prevalence of alterations [3].

FGFR4 GENIE Cases - Top Diseases

The most common alterations in FGFR4 are FGFR4 Mutation (1.65%), FGFR4 Amplification (0.16%), FGFR4 Loss (0.05%), FGFR4 V550L (0.02%), and FGFR4 R219C (0.02%) [3].

FGFR4 GENIE Cases - Top Alterations

Significance of FGFR4 in Diseases

Malignant Solid Tumor +

Urothelial Carcinoma +

Multiple Myeloma +

Cancer +

Breast Carcinoma +

Non-Hodgkin Lymphoma +

Endometrial Carcinoma +

Glioblastoma +

Hepatocellular Carcinoma +

Anaplastic Astrocytoma +

Gastric Carcinoma +

Extrahepatic Cholangiocarcinoma +

Histiocytic And Dendritic Cell Neoplasm +

Squamous Cell Lung Carcinoma +

Lymphoma +

Anaplastic Oligodendroglioma +

Intrahepatic Cholangiocarcinoma +

Cholangiocarcinoma +

Myeloproliferative Neoplasm +

Transitional Cell Carcinoma +

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20170629. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.